Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
Analysis found that dapagliflozin reduces risks of major adverse kidney and CV events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease (HR primary composite outcome: 0.64, 95% CI 0.52–0.79 and 0.50, 0.35–0.72; respectively, p=0.24).
Source:
The Lancet Diabetes & Endocrinology
Resource links:
SPS commentary:
The primary composite outcome was sustained decline in eGFR of at least 50%, end-stage kidney disease, or kidney-related or cardiovascular death.
A commentary suggests that since the study population in DAPA-CKD is representative of about 80–90% of patients with CKD, these results are broadly applicable and impactful. It notes recently, the FDA granted breakthrough therapy designation for dapagliflozin due to the unmet needs addressed by this drug for CKD and that this designation for dapagliflozin is a first in the field of nephrology.